UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15 (d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact Name of Issuer as Specified in Charter)
(State or Other Jurisdiction of Incorporation or Organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices)
(
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8–K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12) |
Pre–commencement communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b)) |
Pre–commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Events
On June 30, 2021, Zynerba Pharmaceuticals, Inc. (the “Company”) announced that its 2021 Annual Meeting of Stockholders, originally scheduled for June 9, 2021 and reconvened on June 29, 2021, was adjourned again due to a lack of the required quorum. The adjourned meeting will be reconvened on August 3, 2021 at 9:00 a.m. Eastern Daylight Time.
The close of business on April 14, 2021 will continue to be the record date for the determination of stockholders of the Company entitled to vote at the Annual Meeting.
On June 30, 2021, the Company issued a press release announcing the adjournment of its 2021 Annual Meeting of Stockholders. A copy of this press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
The following exhibits are being filed herewith:
(d) Exhibits
Exhibit No. |
Document | |
99.1 | Press Release, dated June 30, 2021 | |
104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 30, 2021
ZYNERBA PHARMACEUTICALS, INC. | ||
By: | /s/ Suzanne Hanlon | |
Name: Suzanne Hanlon | ||
Title: Secretary, Vice President and General Counsel |